Skip to main content
SpringerLink
Log in

Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment

  • Chapter
  • First Online:
Molecular & Diagnostic Imaging in Prostate Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1126))

Abstract

Prostate cancer is the most common malignancy in men, and remains the second leading cause of cancer-related death in this gender [1]. Data suggests that 10–20% of patients with prostate cancer metastasis develop castration-resistant prostate cancer (CRPC) within 5 years of follow-up, and that the median survival since development of castration resistance is approximately 14 months (range 9–30) [2]. Additionally, patients with non-metastatic CRPC are at higher risk of disease progression. Approximately 15–33% of patients develop metastasis within 2 years, increasing the mortality burden in this population [3, 4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254 pmid:25559415

    Article  PubMed  Google Scholar 

  2. Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192. https://doi.org/10.1111/j.1742-1241.2011.02799.x pmid:21995694

    Article  CAS  PubMed  Google Scholar 

  3. Hirst CJ, Cabrera C, Kirby M (2012) Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Cancer Epidemiol 36:e349–e353. https://doi.org/10.1016/j.canep.2012.07.012 pmid:22910034

    Article  CAS  PubMed  Google Scholar 

  4. Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918–2925. https://doi.org/10.1200/JCO.2005.01.529 pmid:15860850

    Article  PubMed  Google Scholar 

  5. Tannock IF, de Wit R, Berry WR et al (2004) TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. https://doi.org/10.1056/NEJMoa040720 pmid:15470213

    Article  CAS  PubMed  Google Scholar 

  6. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. https://doi.org/10.1056/NEJMoa041318 pmid:15470214

    Article  CAS  PubMed  Google Scholar 

  7. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G (2015) Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 16:e279–e292. https://doi.org/10.1016/S1470-2045(15)70033-1 pmid:26065613

    Article  PubMed  Google Scholar 

  8. Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. https://doi.org/10.1056/NEJMoa1315815 pmid:25184630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501–5511. https://doi.org/10.1038/onc.2013.206 pmid:23752182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76–85. https://doi.org/10.1038/ncpuro1296 pmid:19198621

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G (2010) Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5:e13500. https://doi.org/10.1371/journal.pone.0013500 pmid:20976069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stein M et al (2014) Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 16:387–400

    Article  PubMed  PubMed Central  Google Scholar 

  13. de Bono JS, Logothetis CJ, Molina A et al (2011) COU-AA-301 investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. https://doi.org/10.1056/NEJMoa1014618 pmid:21612468

    Article  PubMed  PubMed Central  Google Scholar 

  14. Fizazi K, Scher HI, Molina A et al (2012) COU-AA-301 investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992. https://doi.org/10.1016/S1470-2045(12)70379-0 pmid:22995653

    Article  CAS  PubMed  Google Scholar 

  15. Scher HI, Fizazi K, Saad F et al (2012) AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. https://doi.org/10.1056/NEJMoa1207506 pmid:22894553

    Article  CAS  PubMed  Google Scholar 

  16. Ryan CJ, Smith MR, Fizazi K et al (2014) Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer. Ann Oncol 25(Sppl 4):iv255–iv279

    Article  Google Scholar 

  17. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) PREVAIL investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. https://doi.org/10.1056/NEJMoa1405095 pmid:24881730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G (2015) Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 16:e279–e292

    Article  PubMed  Google Scholar 

  19. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  CAS  PubMed  Google Scholar 

  20. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisolone ou mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  21. Pond G et al (2012) Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 61(2):363–369

    Article  CAS  PubMed  Google Scholar 

  22. Kume H et al (2015) Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol 3:303–307

    Article  PubMed  Google Scholar 

  23. Beer T et al (2003) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Br J Cancer 89(6):968–970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Oudard S et al (2015) Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 115(5):744–752

    Article  CAS  PubMed  Google Scholar 

  25. Kellokumpu-Lehtinen PL et al (2013) 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14(2):117–124

    Article  CAS  PubMed  Google Scholar 

  26. Vrignaud P, Semiond D, Lejeune P et al (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in axaneresistant tumors. Clin Cancer Res 19:2973–2983

    Article  CAS  PubMed  Google Scholar 

  27. Oudard S, Fizazi K, Sengeløv L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35(28):3189–3197

    Article  CAS  PubMed  Google Scholar 

  28. Eisenberger M, Hardy-Bessard AC, Kim CS et al (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35(28):3198–3206

    Article  CAS  PubMed  Google Scholar 

  29. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  30. Kantoff P et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  CAS  PubMed  Google Scholar 

  31. Parker C, Nilsson S, Heinrich D et al (2013) ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. https://doi.org/10.1056/NEJMoa1213755 pmid:23863050

    Article  CAS  PubMed  Google Scholar 

  32. Hoskin P, Sartor O, O’Sullivan JM et al (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397–1406. https://doi.org/10.1016/S1470-2045(14)70474-7 pmid:25439694

    Article  CAS  PubMed  Google Scholar 

  33. Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038

    Article  PubMed  PubMed Central  Google Scholar 

  34. Antonarakis ES, Lu C, Luber B et al (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1(5):582–591

    Article  PubMed  PubMed Central  Google Scholar 

  35. Scher H, Graf RP, Schreiber NA et al (2018) Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 36(Suppl 6S):abstr 273

    Article  Google Scholar 

  36. Scher H, Lu D, Schreiber NA et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441–1449

    Article  PubMed  PubMed Central  Google Scholar 

  37. Scher HI, Fizazi SK, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    Article  CAS  PubMed  Google Scholar 

  38. ClinicalTrials.gov (acedido em 25/09/2015). A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL)

  39. Armstrong AJ, Garrett-Mayer ES, Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13(21):6396–6403

    Article  CAS  PubMed  Google Scholar 

  40. Loriot Y, Massard C, Albiges L et al (2012) Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol 30(Suppl 5):abstr 213

    Article  Google Scholar 

  41. Angelergues A, Maillet D, Fléchon A et al (2014) Duration of response to androgen-deprivation therapy and efficacy of secondary hormone therapy, docetaxel, and cabazitaxel in metastatic castration-resistant prostate cancer. J Clin Oncol 32(Suppl 4):abstr 282

    Article  Google Scholar 

  42. Sweeney C, Chen YH, Carducci MA et al (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 32(5 suppl):abstr LBA2

    Article  Google Scholar 

  43. ClinicalTrials.gov (acedido em 25/09/2015) STAMPEDE: systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy: a multi-stage multi-arm randomised controlled trial

  44. Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo controlled phase 3 study. Lancet Oncol 13:983–992

    Article  CAS  PubMed  Google Scholar 

  45. Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697–1708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B (2016) Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995

    Article  CAS  PubMed  Google Scholar 

  48. de Bono JS, De Giorgi U, Massard C et al (2016) PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate. Ann Oncol 27(Suppl 6):7180 Abstract

    Google Scholar 

  49. Ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with metastatic castrate-resistant prostate cancer (IPATential150). https://clinicaltrials.gov/ct2/show/NCT03072238

  50. Pritchard CC, Morrissey C, Kumar A et al (2014) Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 5:4988

    Article  CAS  PubMed  Google Scholar 

  51. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Food and Drug Administration, Silver Spring, MD, 30 May 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm

  52. Graff JN, Alumkal JJ, Drake CG et al (2016) Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7:52810–52817

    PubMed  PubMed Central  Google Scholar 

  53. Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90

    Article  CAS  PubMed  Google Scholar 

  54. Kratochwil C, Bruchertseifer F, Rathke H et al (2017) Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58:1624–1631

    Article  CAS  PubMed  Google Scholar 

  55. Hernandez-Hoyos G, Sewell T, Bader R et al (2016) MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 9:2155–2165

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal

    André Mansinho & Daniela Macedo

  2. Department of Oncology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal

    Isabel Fernandes & Luís Costa

  3. Oncology Division, Faculdade de Medicina de Lisboa, Instituto de Medicina Molecular, Lisbon, Portugal

    Isabel Fernandes & Luís Costa

Authors
  1. André Mansinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Macedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luís Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Veterinary Pathobiology, Univ of Missouri-Columbia, Columbia, MO, USA

    Heide Schatten

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mansinho, A., Macedo, D., Fernandes, I., Costa, L. (2018). Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. In: Schatten, H. (eds) Molecular & Diagnostic Imaging in Prostate Cancer. Advances in Experimental Medicine and Biology, vol 1126. Springer, Cham. https://doi.org/10.1007/978-3-319-99286-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation